Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Employee benefits advice for one of the nation's largest providers of telephone and broadband services
Advised one of the nation's largest providers of telephone and broadband services with respect to compensation and employee benefit plan issues in a more
H-D Michigan Inc. v. Top Quality Service Inc.
Represented Harley-Davidson Motor Company in winning a reversal in the United States Court of Appeals, Seventh Circuit. The Court held that more
Special Committee considering strategic alternatives
Represented Independent board members of a North Carolina-based NYSE-listed services business in connection with their consideration of strategic more
Schoenhaus v. Genesco Inc.
The firm served as lead counsel for Genesco Inc. in defense of patent infringement allegations relating to an orthotic device. Plaintiffs asserted a more